Medicine

Cannabis Reflection: The impact on Canada's housing market

Tuesday, October 15, 2019 - 11:00am

Smiths Falls, Ontario is one such market transformed by Canopy Growth, the largest cannabis producer in the world.

Key Points: 
  • Smiths Falls, Ontario is one such market transformed by Canopy Growth, the largest cannabis producer in the world.
  • "The legal cannabis industry is already being credited with invigorating some lagging economies and as a result, those housing markets could soon see a flurry of activity," Alexander adds.
  • Among those already living near a cannabis store:
    Leger is the largest Canadian-owned full-service market research firm.
  • These forward-looking statements include statements regarding housing market conditions and the Company's results of operations, performance and growth.

CLS Holdings Announces Record First Quarter Fiscal 2020 Results

Tuesday, October 15, 2019 - 11:00am

Record consolidated gross profit margin of 50.6% compared to 35.3% in fiscal Q1 2019.

Key Points: 
  • Record consolidated gross profit margin of 50.6% compared to 35.3% in fiscal Q1 2019.
  • Record revenue from the Companys Oasis Cannabis dispensary of $2.1 million, a 96.6% increase over fiscal Q1 2019 revenue of $1.1 million.
  • A 98.4% increase in dispensary customers, from 26,438 (294 average per day) in fiscal Q1 2019 to a record 52,448 (583 average per day) in fiscal Q1 2020.
  • See CLS Holdings USA filings with the SEC and on its SEDAR profile at www.sedar.com for additional details.

Abalos Therapeutics Launches with €12M Series A Round to Develop Novel Immuno-Virotherapies Against Cancer

Tuesday, October 15, 2019 - 10:00am

Abalos Therapeutics announced today a EUR 12 million Series A financing round establishing its operations and leadership.

Key Points: 
  • Abalos Therapeutics announced today a EUR 12 million Series A financing round establishing its operations and leadership.
  • The Companys objective is to develop new immuno-oncology therapeutics based on a specific arenavirus strain that preferentially infects and proliferates in cancer cells generating a strong anti-tumor immune response.
  • The Series A round was co-led by Boehringer Ingelheim Venture Fund (BIVF) and Gruenderfonds Ruhr, with participation from NRW.BANK and High-Tech Gruenderfonds (HTGF).
  • Abalos Therapeutics has harnessed the unique immune stimulation of the arenavirus to develop a novel anti-cancer approach that provides the full breadth of the immune systems power specifically against cancer cells.

Terns Pharmaceuticals to Present Positive Preclinical Data on FXR Agonist TERN-101 at The Liver Meeting® 2019

Tuesday, October 15, 2019 - 10:00am

The data demonstrate that in preclinical models, TERN-101 was preferentially delivered to the liver, which enables a robust, localized effect on FXR, while potentially mitigating non-liver mediated adverse effects.

Key Points: 
  • The data demonstrate that in preclinical models, TERN-101 was preferentially delivered to the liver, which enables a robust, localized effect on FXR, while potentially mitigating non-liver mediated adverse effects.
  • Our preclinical data show that TERN-101 is efficiently enriched in the liver, the target organ for FXR activity against NASH, which could potentially mitigate non-liver mediated tolerability issues associated with systemic FXR activation.
  • At The International Liver Congress 2019 in Vienna, Terns presented preclinical data demonstrating that TERN-101 reduced liver steatosis, inflammation, ballooning, and fibrosis in a preclinical model of non-alcoholic steatohepatitis (NASH).
  • NASH is associated with chronic liver inflammation and liver cell injury, and it can lead to fibrosis, cirrhosis, and eventually liver cancer or liver failure.

greenbox Robotics Partners with Solvent for Payment Processing

Tuesday, October 15, 2019 - 10:00am

MARINA DEL RAY, Calif., Oct. 15, 2019 /PRNewswire-PRWeb/ --greenbox Robotics, manufacturers of the world's first robotic CBD and cannabis retailers, announced today a strategic partnership with Solvent for payment processing.

Key Points: 
  • MARINA DEL RAY, Calif., Oct. 15, 2019 /PRNewswire-PRWeb/ --greenbox Robotics, manufacturers of the world's first robotic CBD and cannabis retailers, announced today a strategic partnership with Solvent for payment processing.
  • "The CBD & cannabis industry continues to struggle with the issue of finding safe and reliable payment processing.
  • Partnering with Solvent as the compliance-driven payment enabler for our robots is a strategic and symbiotic relationship that adds massive value to our business," says greenbox Robotics CEO Zack Johnson.
  • "Solvent is the only payment enabler that supports fully unmanned solutions," says Ian Cathcart, head of business development for greenbox.

AgraFlora Organics Asserts Cross Functional Integration of Pharmaceutical Grade Bottle Cap, Regional Cannabis Trademarks and CBD Sports Products into 17,500 North American Locations

Tuesday, October 15, 2019 - 8:05am

AgraFloras patented, pharmaceutical grade and hermetically sealed dispensing technology (the Pharma-Grade Bottle Cap) is designed to preserve volatile ingredients such as cannabinoids (CBD/THC/CBDA/CBG), antibiotics, probiotics, vitamins, and minerals.

Key Points: 
  • AgraFloras patented, pharmaceutical grade and hermetically sealed dispensing technology (the Pharma-Grade Bottle Cap) is designed to preserve volatile ingredients such as cannabinoids (CBD/THC/CBDA/CBG), antibiotics, probiotics, vitamins, and minerals.
  • AgraFlora is of the opinion that its Cannabis Trademarks exhibit unrivalled branding potential for the cannabis space.
  • About AgraFlora Organics International Inc.
    AgraFlora Organics International Inc. is a growth oriented and diversified company focused on the international cannabis industry.
  • AgraFlora has a successful record of creating shareholder value and is actively pursuing other opportunities within the cannabis industry.

Philips introduces new 200mm and 150mm Stellarex 0.035” low-dose drug-coated balloons to broaden treatment options for peripheral artery disease patients

Tuesday, October 15, 2019 - 9:00am

The new balloons broaden physicians treatment options for peripheral artery disease (PAD) patients with a high risk of restenosis and expand the Stellarex portfolio, which has a proven significant treatment effect and high safety profile.

Key Points: 
  • The new balloons broaden physicians treatment options for peripheral artery disease (PAD) patients with a high risk of restenosis and expand the Stellarex portfolio, which has a proven significant treatment effect and high safety profile.
  • The 200mm and 150mm Stellarex 0.035 low-dose DCBs are now available in the U.S. and will be rolled out to other markets in due course.
  • Broadening physicians treatment options helps ensure more PAD patients will receive treatment before the disease progresses.
  • Our integrated solutions advance minimally invasive procedures for patients with coronary artery disease, peripheral artery disease and lead extraction indications.

Global Percutaneous Transluminal Coronary Angioplasty (PTCA) Balloon Catheters Industry

Monday, October 14, 2019 - 11:05pm

Balloon Catheters Market in Europe: A Historic Market

Key Points: 
  • Balloon Catheters Market in Europe: A Historic Market
    Forecasts in US$ Thousand by Product: 2018-2025
    Balloon Catheters Market in Europe in US$ Thousand by Product:
    Forecasts in US$ Thousand by Delivery Platform: 2018-2025
    Forecasts in US$ Thousand by Balloon Material: 2018-2025
    Balloon Catheters Market in France by Product: Estimates and
    (PTCA) Balloon Catheters Market Share Analysis by Product: 2009
    Balloon Catheters Market in France by Delivery Platform:
    Balloon Catheters Market in France by Balloon Material:
    Balloon Catheters Market in Germany: Recent Past, Current and
    (PTCA) Balloon Catheters Market Share Breakdown by Product:
    Balloon Catheters Market in Germany: Recent Past, Current and
    Balloon Catheters Market in Germany: Recent Past, Current and
    Angioplasty (PTCA) Balloon Catheters Market by Product:
    Percentage Breakdown of Sales for 2009, 2019, and 2025
    US$ Thousand by Delivery Platform: 2009-2017
    Platform: Percentage Breakdown of Sales for 2009, 2019, and
    US$ Thousand by Balloon Material: 2009-2017
    Material: Percentage Breakdown of Sales for 2009, 2019, and
    Coronary Angioplasty (PTCA) Balloon Catheters: Annual Sales
    (PTCA) Balloon Catheters Market in the United Kingdom: Historic
    Coronary Angioplasty (PTCA) Balloon Catheters: Annual Sales
    (PTCA) Balloon Catheters Market in the United Kingdom: Historic
    Coronary Angioplasty (PTCA) Balloon Catheters: Annual Sales
    (PTCA) Balloon Catheters Market in the United Kingdom: Historic
    Forecasts in US$ Thousand by Product: 2018 to 2025
    (PTCA) Balloon Catheters Market in Spain: Percentage Share
    Breakdown of Sales by Product for 2009, 2019, and 2025
    Forecasts in US$ Thousand by Delivery Platform: 2018 to 2025
    Delivery Platform in US$ Thousand: 2009-2017
    (PTCA) Balloon Catheters Market in Spain: Percentage Share
    Breakdown of Sales by Delivery Platform for 2009, 2019, and
    Forecasts in US$ Thousand by Balloon Material: 2018 to 2025
    Balloon Material in US$ Thousand: 2009-2017
    (PTCA) Balloon Catheters Market in Spain: Percentage Share
    Breakdown of Sales by Balloon Material for 2009, 2019, and 2025
    Projections in US$ Thousand by Product: 2018 to 2025
    (PTCA) Balloon Catheters Market in Russia by Product: A
    Projections in US$ Thousand by Delivery Platform: 2018 to 2025
    (PTCA) Balloon Catheters Market in Russia by Delivery Platform:
    Projections in US$ Thousand by Balloon Material: 2018 to 2025
    (PTCA) Balloon Catheters Market in Russia by Balloon Material:
    Forecasts in US$ Thousand by Product: 2018-2025
    Forecasts in US$ Thousand by Delivery Platform: 2018-2025
    Forecasts in US$ Thousand by Balloon Material: 2018-2025
    Forecasts in US$ Thousand by Region/Country: 2018-2025
    (PTCA) Balloon Catheters Market in Asia-Pacific: Historic
    (PTCA) Balloon Catheters Market in Asia-Pacific by Product:
    in US$ Thousand by Product: 2009-2017
    in US$ Thousand by Delivery Platform: 2009-2017
    in US$ Thousand by Balloon Material: 2009-2017
    (PTCA) Balloon Catheters Market in Australia: Recent Past,
    in US$ Thousand by Product: 2009-2017
    (PTCA) Balloon Catheters Market in Australia: Recent Past,
    in US$ Thousand by Delivery Platform: 2009-2017
    (PTCA) Balloon Catheters Market in Australia: Recent Past,
    in US$ Thousand by Balloon Material: 2009-2017
    Forecasts in US$ Thousand by Product: 2018 to 2025
    (PTCA) Balloon Catheters Market in India: Percentage Share
    Breakdown of Sales by Product for 2009, 2019, and 2025
    Forecasts in US$ Thousand by Delivery Platform: 2018 to 2025
    Delivery Platform in US$ Thousand: 2009-2017
    (PTCA) Balloon Catheters Market in India: Percentage Share
    Breakdown of Sales by Delivery Platform for 2009, 2019, and
    Forecasts in US$ Thousand by Balloon Material: 2018 to 2025
    Balloon Material in US$ Thousand: 2009-2017
    (PTCA) Balloon Catheters Market in India: Percentage Share
    Breakdown of Sales by Balloon Material for 2009, 2019, and 2025
    (PTCA) Balloon Catheters Market in South Korea: Recent Past,
    in US$ Thousand by Product: 2009-2017
    (PTCA) Balloon Catheters Market in South Korea: Recent Past,
    in US$ Thousand by Delivery Platform: 2009-2017
    (PTCA) Balloon Catheters Market in South Korea: Recent Past,
    in US$ Thousand by Balloon Material: 2009-2017
    Transluminal Coronary Angioplasty (PTCA) Balloon Catheters:
    (PTCA) Balloon Catheters Market in Rest of Asia-Pacific:
    Transluminal Coronary Angioplasty (PTCA) Balloon Catheters:
    (PTCA) Balloon Catheters Market in Rest of Asia-Pacific:
    ReportLinker is an award-winning market research solution.
  • Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

Silk Road Medical to Report Third Quarter 2019 Financial Results on October 29, 2019

Monday, October 14, 2019 - 9:05pm

SUNNYVALE, Calif., Oct. 14, 2019 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced it will report financial results for the third quarter 2019 after market close on Tuesday, October 29, 2019.

Key Points: 
  • SUNNYVALE, Calif., Oct. 14, 2019 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced it will report financial results for the third quarter 2019 after market close on Tuesday, October 29, 2019.
  • Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
  • Silk Road Medical, Inc. is a medical device company located in Sunnyvale, California, that is focused on reducing the risk of stroke and its devastating impact.
  • The company has pioneered a new approach for the treatment of carotid artery disease called TransCarotid Artery Revascularization (TCAR).

Tandem Diabetes Care to Announce Third Quarter 2019 Financial Results on November 4, 2019

Monday, October 14, 2019 - 9:05pm

Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, plans to release its third quarter 2019 results after the financial markets close on Monday, November 4, 2019.

Key Points: 
  • Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, plans to release its third quarter 2019 results after the financial markets close on Monday, November 4, 2019.
  • The Company will hold a conference call and simultaneous webcast on the same day at 4:30pm Eastern Time (1:30pm Pacific Time), to discuss its third quarter 2019 financial and operating results.
  • Tandem Diabetes Care, Inc. ( www.tandemdiabetes.com ) is a medical device company dedicated to improving the lives of people with diabetes through relentless innovation and revolutionary customer experience.
  • Tandem Diabetes Care is a registered trademark and t:slim X2 is a trademark of Tandem Diabetes Care, Inc.
    View source version on businesswire.com: https://www.businesswire.com/news/home/20191014005644/en/